



PATENT
ATTORNEY DOCKET NO. 00786/457003

Certificate of Mailing: Date of Deposit: August 21, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sarah Wilcox

Printed name of person mailing correspondence

Sarah Wilcox

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Faustman et al.	Confirmation No.:	1044
Serial No.:	10/775,487	Art Unit:	1644
Filed:	February 10, 2004	Examiner:	Zachary S. Skelding
Customer No.:	21559		
Title:	METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE DISEASE		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after the mailing of a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. I, the undersigned, hereby certify that each item of information contained in this statement was first cited in a communication from a foreign patent office in a counterpart foreign application, dated July 13, 2007, which is not more than three months prior to the filing of this statement.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 13 August 2007



for Paul T. Clark
Reg. No. 30,162

TOOD ARMSTRONG, Ph.D.
Reg. No. 54,590

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/457003
	Serial No.	10/775,487
	Applicant	Faustman et al.
	Filing Date	February 10, 2004
	Group	1644
	IDS Filed	August 21, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	WO 95/25533	09/28/1995	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Hartwell et al., "Aberrant Cytokine Regulation in Macrophages from Young Autoimmune-Prone Mice: Evidence that the Intrinsic Defect in MRL Macrophage IL-1 Expression is Transcriptionally Controlled," <i>Mol. Imm.</i> 32: 743-751, 1995.
	Hayashi et al., "NOD Mice are Defective in Proteasome Production and Activation of NF- κ B," <i>Mol. Cell. Biol.</i> 19: 8646-8659, 1999.
	Rolfe et al., "The Ubiquitin-Mediated Proteolytic Pathway as a Therapeutic Area," <i>J. Mol. Med.</i> 75: 5-17, 1997.
	Yan et al., "Reduced Expression of <i>Tap1</i> and <i>Lmp2</i> Antigen-Processing Genes in the Nonobese Diabetic (NOD) Mouse Due to a Mutation in Their Shared Bidirectional Promoter," <i>J. Immun.</i> 159: 3068-3080, 1997.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	